biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Midatech $0.9489 +$0.1189 (14.32%) Today

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Dec 30, 2022 3:21pm

175 Views

Post# 35197573

Midatech $0.9489 +$0.1189 (14.32%) Today

Denali starting to sweat?

With a potential US$20 million infusion of cash providing escape velocity to key catalysts;
cancer assets to establish a leadership position in brain delivery for cancer;
Q-Sphera validated by J&J and allowing xB3 to leap-frog Denali's technology;
and Chiesi about to become a strategic force in LSDs as Biodexa becomes a development company and releases Hunter data in Q2... This isn't the catastrophically undercapitalized BTI of the past!

This is a revolution!

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal